ACN Newswire 

Paying Off Debt but Still Want to Save? Here’s How to Manage Both

SINGAPORE, May 18, 2026 - (ACN Newswire via SeaPRwire.com) - Want to rebuild your savings while carrying an existing debt? It can be overwhelming, but it is possible. The common belief is that one must eliminate all debt before saving again, but this could not be further from reality. Both goals can be managed together, even with monthly bills, Equated Monthly Instalments (EMIs) and everyday expenses competing for your income.A balanced approach to savings can reduce financial stress, help to stay prepared for emergencies and move steadily towards long-term stability. Some short-term options to help paying off debt include a Balance Transfer, Personal Loan or a credit line. Choosing the suitable Balance Transfer option available can help lower interest costs and make repayment more manageable.Wondering how? Read along to find out.Get a clear picture of your current financesBefore creating an aggressive savings plan or an unrealistic debt payment plan that will soon drain you, it is important to understand where your money is going. As a first step, list all your outstanding debts, including credit cards, personal loans or education loans, along with their respective interest rates and required minimum payments. While doing this, also consider your monthly income and essential expenses to understand the flexibility you have.Budget for both goalsRebuilding your savings starts with setting a well-structured budget. Many people often allocate every bit of extra money towards debt repayment, which is why they fail to rebuild their savings. Allocate specific portions to both savings and debt reduction, striking a balance that ensures you do not feel financially insecure while you work towards freedom from debt. Over time, your budget can be adjusted as debts reduce and your financial confidence grows.Start with an emergency fundAn emergency fund protects you from unexpected expenses that could push you further into debt. This fund helps cover medical emergencies, urgent travel or sudden job changes/loss, without relying on credit cards or loans. Building this fund steadily, no matter the amount, is more important than trying to save a large sum all at once.Reduce debt while protecting your savingsIf you want to stay consistent with repayments without sacrificing your savings, you must choose the right strategy, which balances interest payment, motivation and cash flow. The right approach depends on whether you want to minimise interest or maintain motivation while saving. The debt avalanche method focuses on the former, while the snowball method helps with the latter.Debt avalanche methodUnder this method, the focus is on paying off debts with the highest interest first, while continuing to make minimum payments on others. This reduces the total interest paid over time, whereby you regain control. This repayment strategy reduces the interest burden and frees up money that can be later redirected towards savings.Debt snowball methodThe snowball method focuses on clearing smaller debts first, focusing on quick wins that result in continued motivation. With each debt cleared, the available amount can be split between savings and the next payment goal.Automate savingsThe temptation to skip saving when expenses rise can be strong; hence, automating your savings is important. For instance, setting up a mandate for automatic transfer of funds to your savings account right after your salary is credited ensures consistency. This helps you maintain steady and growing savings while also staying committed to debt repayment.Cut expenses without feeling restrictedReducing expenses does not require extreme cutbacks. Identify areas where you can make small adjustments that will lead to significant savings. This includes checking for unused subscriptions, planning meals to limit dine-out expenses, and reviewing bills wherever possible. The freed-up money can later be allocated to savings or debt payments.Rebuilding your savings while paying off existing debt is a long-term game of patience, planning and consistency. Start by understanding your finances and then identifying a financial strategy that works best for you. Saving and debt repayment are not competing goals, they can work together to create a secure financial future.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB Ltd.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Carbonverse Pioneers a New Ecosystem of “Carbon Assets + Digital Wallet + Use-to-Earn”

HONG KONG, May 18, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, Carbonverse Limited and Wanel Capital Limited officially signed a cooperation agreement to establish a joint venture. Centered on three core pillars—carbon assets, digital wallets, and the "use-to-earn" (utility mining) model—the joint venture will integrate technical strengths with real-world scenarios. This initiative aims to drive carbon assets out of the industrial sector and directly into the consumer market, building a future-ready green value ecosystem.Carbonverse possesses mature practices and full-stack capabilities in carbon asset management, green finance scenario implementation, and carbon credit trading. Leveraging this partnership, the platform will further strengthen its digital wallet underlying technology, security systems, and development capabilities, creating an innovative infrastructure that deeply integrates "carbon assets + digital wallets + use-to-earn."Mr. Liang Liang, Chairman of Carbonverse, stated that this collaboration marks a critical milestone in executing the company's core strategy, following the successful completion of Carbonverse's underlying carbon asset layout and strategic tool systems. With carbon assets acting as the core vehicle, the top-level design will systematically dismantle three traditional barriers:- Breaking Scenario Barriers: Moving carbon assets beyond the traditional To-B (Business) and To-G (Government) sectors, allowing them to penetrate the mass consumer (To-C) market. Through the "use-to-earn" model, Carbonverse will cover everyday scenarios such as EV charging, commuting, smart homes, and health appliances, completing a pivotal leap for the carbon economy from industrial markets to consumer markets.- Breaking User Barriers: Building a unified entry point and asset closed-loop via a green digital wallet. This will enable the monetization of user attention and behavioral value, fostering deep integration and seamless value interoperability between the online digital ecosystem and offline private domain users.- Breaking Technology & Ecosystem Barriers: Seizing the historic opportunity where AI reshapes the global industrial landscape to construct a future-proof, three-in-one core competitiveness powered by carbon computing power, attention data, and intelligent operations.Under this strategic framework, the joint venture will leverage the large-scale circulation of carbon assets across online consumer platforms to establish highly efficient pricing and liquidity capabilities.Simultaneously, through innovative operational models—such as use-to-earn mechanisms, carbon blind boxes, and IP co-branded ecosystems—the platform will cultivate high-value, high-stickiness, and high-LTV (lifetime value) user assets. This will establish a virtuous cycle driven by data monetization, attention monetization, time monetization, and community value feedback.Looking ahead, Carbonverse will continue to deepen its strategic tools and ecosystem deployment. By deeply integrating artificial intelligence, Carbonverse aims to make AI a vital engine driving the convergence and innovation of the carbon ecosystem, digital assets, private domain value, and green finance, ultimately expanding its strategic runway for the future.About CarbonverseCarbonverse Limited, a subsidiary of C Dimension, is an innovative platform specializing in carbon asset digitalization and green initiatives. The company is dedicated to driving the transformation of carbon assets from mere compliance tools into premium financial assets, building a next-generation green consumer carbon ecosystem powered by use-to-earn mechanisms, generalized carbon inclusion, and attention monetization. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Tyson Fury, The Gypsy King, Joins Datavault AI as International Spokesperson to Champion Athlete Data Monetization

PHILADELPHIA, PA, May 18, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today announced that two-time world heavyweight champion Tyson Fury has signed on as International Spokesperson for Datavault AI a deal brokered by Nick Hunter of P11.Ranked No. 3 on Forbes' 2025 list of the world's highest-paid athletes with $146 million in estimated earnings (Forbes 2025), Fury brings global star power, and a uniquely personal understanding of what it means to own, protect, and capitalize on a name, to Datavault AI's mission of empowering individuals and organizations to monetize their data and digital assets. Known worldwide as "The Gypsy King," his appointment immediately precedes the launch of the Sports Illustrated Exchange, Datavault AI's solution designed to address the Name, Image, and Likeness (NIL) monetization challenges facing athletes, influencers, and rights holders across professional and collegiate sports."We have the utmost respect for Tyson Fury, not only as one of the greatest heavyweight champions of all time, but as a resilient warrior whose strength and authenticity make him the perfect partner for the battles ahead. Raising global awareness for Name, Image, and Likeness monetization, while confronting the critical importance of cyber security in the face of the coming quantum leap, are among the toughest challenges companies encounter today. Tyson Fury is strong enough to confront these head-on alongside Datavault AI's Quantum Secure Data Monetization platform, and his involvement will accelerate awareness of our AI-powered solutions, including the Information Data Exchange® (IDE), which securely attaches real-world assets to immutable metadata for responsible monetization. The Sports Illustrated Exchange will transform how athletes capitalize on their NIL rights, and having Fury as our international face underscores the scale and legitimacy of this initiative," said Nathaniel T. Bradley, CEO of Datavault AI.Fury, whose larger-than-life personality and crossover appeal have captivated audiences beyond the ring, stated: "I've spent my career fighting for what's mine inside and outside the ropes. Datavault AI is giving athletes and creators the tools to truly own and profit from their name, image, likeness, and data in the digital age. I'm proud to join the team and help bring the Sports Illustrated Exchange to the world. It's going to be massive," said Tyson Fury, the Former Unified, Ring, and Lineal Heavyweight Champion of the World.About Tyson FuryTyson Fury is a two-time world heavyweight champion and one of the most decorated fighters of his generation, with a professional record of 34 wins (24 by knockout), 2 losses, and 1 draw across 37 professional fights. A two-time Ring magazine Fighter of the Year -- earning the honor in 2015 for his upset of long-reigning champion Wladimir Klitschko and again in 2020 following his dominant rematch victory over Deontay Wilder -- Fury is the only heavyweight to hold The Ring magazine title twice since Muhammad Ali, joining Floyd Patterson and Ali as the three men to achieve that distinction. His 2021 trilogy fight with Wilder was named Fight of the Year by The Ring.Ranked No. 3 among the world's highest-paid athletes in 2025 by Forbes at $146 million in estimated earnings Forbes 2025, Fury is recognized as one of the most commercially powerful athletes on the planet and the highest-earning individual sport athlete in the United Kingdom. He commands a combined social media following of more than 11 million -- 6.9 million on Instagram, 2.2 million on X, and 2.2 million on Facebook -- extending his reach across sports, entertainment, and lifestyle audiences in the United Kingdom, continental Europe, the United States, and beyond.Standing 6'9" with an 85-inch reach, Fury is known globally for his technical range in the ring and his equally powerful story outside it -- a years-long public comeback from mental health challenges, including bipolar disorder, that has made him one of sport's most recognized advocates for mental health awareness. That authenticity, combined with his platform, makes him a natural fit for a company built on the principle that individuals should own and control the value of who they are.Off the canvas, Fury stars in the Netflix series At Home with the Furys. Season 2 debuted on April 12, 2026 -- timed to coincide with Fury's live Netflix return fight against Arslanbek Makhmudov the night before -- and Netflix has already renewed the series for a third season. This partnership positions Datavault AI to expand its reach across sports, entertainment, and Web 3.0 sectors as the Company prepares to launch the Sports Illustrated Exchange later in 2026.About Datavault AIDatavault AI™ (NASDAQ:DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization.Datavault AI's platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company's technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring.The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, statements regarding the engagement of Tyson Fury as International Spokesperson, the planned launch of the Sports Illustrated Exchange, expected market reception of name, image, and likeness monetization products, anticipated customer engagements, and projected operating performance. These statements may be identified by words such as "may," "will," "expect," "anticipate," "intend," "plan," "believe," "estimate," and similar expressions.Forward-looking statements are based on management's current expectations and assumptions and are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Such factors include, without limitation: risks associated with spokesperson and endorsement arrangements; the Company's ability to launch and commercialize the Sports Illustrated Exchange on the anticipated timeline; competitive conditions in the AI computing, sports, and digital licensing markets; regulatory and compliance risks affecting name, image, and likeness monetization; technological development and integration risks; financing availability; and the other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission, including the Risk Factors section of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.Readers are cautioned not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this release except as required by law.Industry and Market DataWithin this press release, we reference information and statistics regarding market rankings and athlete earnings data. We have obtained some of this information from independent third-party sources, including Forbes and The Conversation/University of Western Australia Business School. Some data are also based on management's estimates and calculations. While we believe such information is reliable, we have not independently verified any third-party information. Data regarding market position, rankings, and industry statistics are inherently imprecise and subject to significant business, economic, and competitive uncertainties beyond our control.Media Contact:marketing@dvlt.aiInvestor Contact:Edward BargerVP, Investor Relationsebarger@dvlt.ai | ir@dvlt.aiSOURCE: Datavault AI Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning

SINGAPORE, May 15, 2026 - (ACN Newswire via SeaPRwire.com) - Travel goals often begin as ideas scribbled in a notebook or saved Instagram posts but turning them into real experiences can take thoughtful planning. One practical way travellers in Singapore explore these goals is by understanding how Travel Credit Cards can fit into their overall travel checklist. When used mindfully, the right card rewards can help reduce travel-related expenses and make trips feel more achievable. From flights and accommodation to daily spending abroad, a structured approach can help travellers make the most of what they already spend.This checklist is designed to help review travel plans and see how card rewards can support those goals in a realistic, manageable way.Define Your Travel Goals ClearlyClear travel goals provide direction and make planning feel less overwhelming. Instead of a vague plan to "travel more," it helps to identify destinations, timelines, and travel styles. For instance, a short regional trip to Bangkok or Bali may involve different costs and priorities compared to a longer holiday to Europe or Australia. In Singapore, a return flight within Southeast Asia can range between SGD 200 and SGD 500, while long-haul flights may cross SGD 1,200.Understand How Travel Rewards Fit Into Your PlansTravel rewards work best when they match existing spending patterns rather than forcing new habits. Many Travel Credit Cards in Singapore offer reward points or miles on everyday categories, such as dining, online shopping, and transport. Over time, these points can help offset flight bookings or hotel stays. This makes it easier to assess how everyday spending may contribute to future travel plans.Track Your Expenses and Reward PotentialTracking spending is an important part of reviewing how realistic travel goals are. Monthly expenses, such as groceries, utilities, and subscriptions, often total between SGD 1,500 and SGD 2,500 for many households in Singapore. When these expenses are channelled through cards offering travel rewards, points can accumulate gradually. Keeping a simple monthly record can also highlight which categories generate the most rewards.Check Reward Redemption Options and FlexibilityNot all rewards work the same way, so you should review redemption options. Some cards allow points to be converted into airline miles, while others offer travel vouchers or statement credits for travel bookings. Flexibility matters, especially for travellers who prefer multiple airlines or travel dates. Understanding the terms and conditions of rewards also helps clarify what is actually usable for your plans.Review Travel-Related Benefits Beyond RewardsMany Travel Credit Cards come with additional benefits, such as airport lounge access, travel insurance coverage, or discounts on hotel bookings. For example, complimentary lounge access at Changi Airport can help reduce pre-flight expenses, where meals alone may cost SGD 20-40. These features may be useful for travellers who value comfort and convenience alongside rewards.Plan for Overseas Spending and Currency CostsOverseas spending is an important part of any travel checklist, especially when travelling frequently. Foreign currency fees often range between 2.5% and 3.5% per transaction, which can add up quickly on longer trips. Some travel-focused cards offer lower foreign currency fees or bonus rewards for overseas spending. This is worth reviewing before choosing a card for regular use abroad.Review Annual Fees Against Real ValueAnnual fees are an important consideration when reviewing travel-related cards. In Singapore, annual fees for Travel Credit Cards can range from SGD 150 to SGD 500. While higher-fee cards often come with more generous rewards or perks, the value depends on individual travel frequency. A traveller taking one or two trips a year may find sufficient value in mid-range options. Reviewing fee waivers, renewal bonuses, and reward redemption potential can give a clearer picture of overall value.Turning Plans Into Meaningful Travel ExperiencesTravel planning does not have to feel complicated or financially overwhelming. With a clear checklist and realistic expectations, travellers in Singapore can review how everyday spending aligns with their travel goals. Travel Credit Cards, when chosen thoughtfully, can help make trips more accessible by offsetting certain costs and adding convenience. The key lies in understanding rewards, tracking progress, and revisiting goals regularly.Disclaimer: This content is published by iQuanti Singapore Pte. Ltd., an external marketer engaged and compensated by UOB Ltd.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform

NESHER, ISRAEL, May 16, 2026 - (ACN Newswire via SeaPRwire.com) - Tabor Electronics today announced the commercial release of its Anti-Drone Test and Evaluation (T&E) solution, introducing a software-defined approach to validating counter-unmanned aircraft systems (C-UAS). Built on the company's Proteus™ Software Defined Radio (SDR) platform, the solution enables defense and security organizations to test and deploy counter-drone technologies in rapidly changing threat environments.As low-cost drones proliferate and communication protocols evolve, traditional hardware-bound test environments are struggling to keep pace. Tabor's platform replaces these constraints with a programmable framework that allows engineering teams to emulate and validate real-world RF scenarios in controlled lab environments-reducing reliance on extended field testing while accelerating development timelines.Originally developed in collaboration with leading anti-drone technology companies, the solution has already been proven in active development and integration workflows. Its commercial release brings a field-tested approach to organizations across defense, homeland security, public safety, and critical infrastructure.At the core of the platform is Tabor's Proteus SDR architecture, combining wideband RF signal generation and acquisition with real-time FPGA processing, deep memory, and high-throughput data movement in a compact COTS system. This integration enables closed-loop testing, where detection and mitigation techniques can be continuously validated and refined under realistic RF conditions.A Shift to Software-Defined ValidationTabor's solution changes how C-UAS systems are tested by moving validation into the lab and enabling rapid iteration through software. New threat scenarios can be introduced without hardware changes, allowing teams to adapt quickly while maintaining consistency between lab validation and real-world performance.This approach delivers clear operational benefits:Faster development and integration cyclesReduced dependence on field testingEnable predictable system performance before deploymentExtended lifespan of test infrastructureBy consolidating multiple RF test functions into a single scalable SDR platform, organizations can also reduce tool fragmentation and improve asset utilization across programs.Proteus SDR Platform OverviewThe Proteus platform is based on a direct digital RF architecture, supporting wide-frequency signal generation and acquisition with high instantaneous bandwidth for accurate threat emulation. Programmable FPGA resources enable real-time adaptability, while flexible form factors-including benchtop, desktop, and PXI-support both component-level development and full system evaluation. Multi-channel phase-coherent operation enables complex, synchronized test scenarios.Mark Elo, Chief Product Officer at Tabor Electronics, commented:"Counter-drone systems are being deployed into environments where threats evolve faster than traditional validation methods can keep up. We built this platform to close that gap-giving teams the ability to test against what's next, not what's already known."About Tabor ElectronicsFounded in 1971, Tabor Electronics is a global provider of signal generation and acquisition solutions serving defense, aerospace, communications, and advanced research markets. The company is known for compact, scalable architecture, long platform lifecycles, and close collaboration with OEMs and system integrators worldwide.For more information: https://info.taborelec.com/drone-test-guideTabor Electronics will present its Anti-Drone Test and Evaluation solution at AOC Europe, 19th -21st May, Helsinki, Finland at Booth 5S13.Follow Us on LinkedIn: https://www.linkedin.com/company/tabor-electronics/Media and Investor Contact:Mark Elo, CPO628-208-6418info@taborelec.comwww.taborelec.comSOURCE: Tabor Electronics Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

S CUBE Capital Announces Strategic Acquisition by InCred Capital to enhance Global Asset Management Capabilities

SINGAPORE, May 18, 2026 - (ACN Newswire via SeaPRwire.com) - S CUBE Capital, a Singapore-based fund management firm regulated by the Monetary Authority of Singapore (MAS), is pleased to announce its strategic acquisition by InCred Capital, the wealth and asset management arm of the InCred Group, subject to regulatory approvals.This milestone brings together S CUBE Capital’s award-winning expertise in fixed income and alternative investments with InCred’s institutional reach, global wealth platform, and deep client franchise across India, Southeast Asia, the Middle East, and London.S CUBE Capital’s flagship fixed income fund was ranked the No. 1 in Asia Pacific by Bloomberg for the year ending January 2026. The firm was also named “Best Asset Management Firm – Singapore & Southeast Asia” by WealthBriefingAsia. Through this acquisition, S CUBE Capital’s clients and partners will benefit from a stronger institutional platform, broader investment capabilities, and a more seamless bridge for capital flows across key regional corridors.As part of the transition, S CUBE Capital’s Co-founders, Hemant Mishr and Balaji Swaminathan, along with key members of the S CUBE team, will join InCred Global Wealth. Hemant Mishr and Balaji Swaminathan will assume the roles of Joint Vice Chairmen of the global asset management business and their continued leadership will ensure stability, continuity, and commitment to S CUBE’s investors.Balaji Swaminathan and Hemant Mishr said in a joint statement “By combining S CUBE Capital’s specialized fixed-income and alternatives expertise with InCred’s institutional-grade infrastructure and global wealth platform, we are significantly expanding our ability to offer bespoke investment strategies and diversified investment products. For our investors, this means access to a broader opportunity set, deeper institutional support, and the continued high-touch service model that has defined S CUBE Capital.”“We have acquired S CUBE Capital to further strengthen our offshore product suite and global alternatives platform. As we continue to scale from a position of strength in India, S CUBE’s proven expertise in fixed income and alternatives enhances our global asset and wealth management platform and strengthens our ability to offer clients differentiated offshore investment opportunities across key regional corridors,” said Bhupinder Singh, founder, InCred Group.Srikantan Selvamani, CEO of InCred Global Wealth, added: “S CUBE Capital’s regulated fund platform, strong investment track record, and deep expertise in fixed income and alternative investments make it a natural fit for our global wealth business. Together, we are building a differentiated cross-border platform designed to serve the evolving needs of UHNIs, family offices, and institutional investors.”InCred Global Wealth operates across Singapore, Dubai, and London, offering wealth and asset management solutions spanning investments, credit, and legacy planning for ultra-high-net-worth individuals (UHNIs), high-net-worth individuals (HNIs), family offices, and institutional investors.The business currently oversees more than Rs 1 lakh crore (approximately US$10.5 billion) in wealth assets under management and approximately Rs 10,000 crore (US$1 billion) in asset management AUM.About SCUBE Capital(https://scubecapital.com/)S CUBE is a global fund management company domiciled in Singapore and regulated by the Monetary Authority of Singapore (MAS). We are a strong and dedicated team of internationally experienced experts delivering institutional investment expertise to client. Our team has managed investments of over USD50 billion in our previous roles and has a cumulative experience of over 100years in Global Financial Markets across assets includingCredit, Equities, Fixed Income,Rates,FXand Commodities.Media Contact:Namrata SharmaNamrata.sharma@adfactorspr.com+6581383034 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Shoucheng Holdings’ First-Quarter Report Shows 18% Core Profit Growth and Sustained High Shareholder Returns

HONG KONG, May 16, 2026 - (ACN Newswire via SeaPRwire.com) - Against the backdrop of continued momentum in artificial intelligence and the robotics industry, Shoucheng Holdings (697.HK) released its first-quarter 2026 report on May 15. The report highlighted the company’s operational resilience and financial safety margin, further strengthening market expectations for a long-term revaluation of the company.In terms of core operating data, the company continued to improve its earnings quality. Excluding the impact of one-off gains, Shoucheng Holdings’ net profit attributable to shareholders rose 18% year on year in the first quarter, reflecting the steady improvement in the recurring profitability of its core businesses.Market observers believe this indicates that the company’s recent deployments in infrastructure asset management, industrial park operations, robotics, and intelligent manufacturing ecosystem investments are gradually entering a stage of return realization. Its ability to maintain stable profit growth at the operating level demonstrates a degree of counter-cyclical resilience in its business structure.As of the end of the first quarter of 2026, Shoucheng Holdings held approximately HK$7.279 billion in cash and cash equivalents, while its interest-bearing debt ratio was only 6.3%, reflecting a sound overall asset-liability structure. The company’s low leverage and high cash reserves not only strengthen its ability to withstand external market volatility, but also provide sufficient resources for continued investment in emerging industries, the expansion of its REITs ecosystem, and the advancement of its robotics industry chain layout.The company has continued to implement a high shareholder-return strategy. The board of directors declared a special dividend of HK$470 million, while the company repurchased approximately HK$175 million worth of shares during the first quarter. These actions reflect management’s strong confidence in the company’s future development and cash flow position. For Hong Kong equity investors, in a market environment that remains volatile, companies combining growth potential with stable shareholder returns are often more likely to attract medium- and long-term capital.With Shoucheng Holdings’ first-quarter results continuing to follow the three main themes of earnings recovery, financial stability, and enhanced shareholder returns, market observers believe that the company’s valuation still has room for continued revaluation as robotics commercialization, REITs asset recycling, and infrastructure operation capabilities are further unlocked. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program

Highlights:WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutionsCombination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmaciesProposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordinationProposed transaction valued at approximately $15 millionStrategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providersTAMPA, FLA., May 15, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million, with the balance to be satisfied through a performance-based earnout issued in preferred stock.WellCare Today is a healthcare technology and remote monitoring company focused on chronic care management ("CCM"), remote patient monitoring ("RPM"), and remote therapeutic monitoring ("RTM") programs. The company delivers HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its broader Health Monitoring & Emergency Support Ecosystem. The platform enables passive, continuous monitoring of key health metrics including heart rate, blood oxygen levels, temperature, sleep patterns, activity tracking, and self-reported medication adherence through Medicare-reimbursable RPM and RTM programs. No assurance can be given that any particular patient, provider, pharmacy, service, device or workflow will qualify for reimbursement.Under the proposed transaction structure, Wellgistics Health intends to integrate WellCare Today's HealthAssist® platform and RPM, RTM and CCM capabilities with the Company's recently announced MSO pilot collaboration involving Kare Clinicals, a division of Kare PharmTech, LLC, as well as its network of more than 6,500 independent pharmacies. The combined infrastructure is intended to support scalable patient engagement, medication adherence initiatives, longitudinal monitoring programs, chronic disease management, and enhanced care coordination workflows across provider and pharmacy channels utilizing connected wearable technologies and remote monitoring infrastructure.The proposed transaction is also expected to create opportunities for participating pharmacies within the Wellgistics Pharmacy Network to engage in clinical service programs associated with RPM, RTM and CCM initiatives, while enabling providers to access scalable care coordination, monitoring, and reimbursement infrastructure. The companies believe the proposed collaboration may establish a more connected healthcare ecosystem aligning patients, pharmacies, providers, wearable technologies, and longitudinal care coordination services through technology-enabled engagement and remote monitoring platforms.The LOI is non-binding, and completion of the proposed transaction remains subject to customary due diligence, negotiation and execution of definitive agreements, board approvals, financing considerations, and other customary closing conditions. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be completed as currently contemplated, or at all.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.About WellCare Today, LLCWellCare Today is a healthcare technology company delivering HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its comprehensive Health Monitoring & Emergency Support Ecosystem. HealthAssist® enables passive, continuous monitoring of key health metrics including hourly heart rate, hourly blood oxygen levels, temperature, daily steps, sleep patterns, and self-reported medication adherence. Integrated with Remote Therapeutic Monitoring (RTM) and Remote Patient Monitoring (RPM) programs reimbursable by Medicare, HealthAssist® delivers an affordable, scalable solution designed to support seniors and individuals managing chronic health conditions.All RPM, RTM, CCM and related care-coordination services are expected to be furnished, supervised, documented and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, and professional practice rules. The Company does not provide medical advice through this press release, and participation in any program will be subject to applicable clinical, contractual, regulatory and reimbursement requirements.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม

Asset Value Investors (AVI) urges the dismissal of two directors at Wacom

LONDON, May 14, 2026 - (ACN Newswire) - Asset Value Investors Limited (“AVI”) has submitted shareholder proposals on one of AVI Japan Opportunity Trust’s (“AJOT”) portfolio companies, Wacom Corporation (TSE: 6727, “Wacom”) calling for board changes ahead of Wacom’s upcoming Annual General Meeting in June. AVI, Wacom’s largest shareholder on behalf of all the portfolios it manages, is seeking the dismissal of two directors and the appointment of one external director. Alongside these proposals, AVI has disclosed additional material on its Wacom campaign, including a detailed presentation on an updated dedicated website (www.DrawWacomsFuture.com). Since initiating its investment in Wacom in August 2021, AVI has sought various forms of engagement aimed at enhancing the company’s long-term corporate value as Wacom’s largest shareholder. However, the Branded Business, one of Wacom’s principal business segments, fell into loss from FY2023/3 onwards, and business growth has stalled amid the implementation of large-scale restructuring measures. Furthermore, AVI has serious concerns regarding Wacom’s governance framework in light of the recently announced inappropriate acquisition of a company represented by one of Wacom’s own outside directors, despite the absence of tangible business synergies with Wacom, as well as the improper use of corporate resources, including the provision of preferential treatment to the children of the company representative director, Mr Ide. In light of these circumstances, AVI, as the company’s largest shareholder and a long-term investor on behalf of all the portfolios it manages, publicly launched a campaign last year to support sustainable improvements in corporate value. This year, AVI has decided to publish additional materials and submit shareholder proposals at the upcoming annual general meeting, as follows: - Appointment of one outside director - Dismissal of two directors (the Representative Director and one outside director) Kaz Sakai, Head of Japan Research at AVI, commented as follows: “Wacom has demonstrated serious deficiencies in governance oversight. These include the acquisition by Wacom of a loss-making company represented by Mr Nakajima, one of its own external directors, for more than ten million dollars, the subsequent transfer of Mr Nakajima into an internal director role, and conduct by Mr Ide, Wacom’s Representative Director and CEO, that can only reasonably be viewed as a conflation of personal and corporate interests, together with a board that has tolerated such behaviour.” “Wacom must restore the proper functioning of its governance framework without delay. In addition to proposing the dismissal of Mr Ide and Mr Nakajima, whom AVI has concluded are central to these governance failures, AVI has also nominated a candidate for outside director capable of strengthening governance and management. We are confident that, through the board structure recommended by AVI and the implementation of operational improvement measures, Wacom can further reinforce its position as the global market leader in the graphic tablet business.” About Asset Value Investors (AVI): AVI is an investment management company established in London, United Kingdom, in 1985. AVI has invested in Japanese equities for more than 40 years. AVI manages AVI Global Trust (AGT) and AVI Japan Opportunity Trust (AJOT) and other funds, collectively investing Y180bn into the Japanese market. AGT and AJOT are public companies whose shares are listed and traded on the main market of the London Stock Exchange. AVI is a signatory to Japan’s Stewardship Code and is committed to constructive engagement with management teams and boards of its portfolio companies, with the aim of contributing to sustainable growth and enhanced enterprise value. AVI’s holding in Wacom on behalf of all its funds is 13.8% making AVI the largest shareholder (as of 30 April 2026). Wacom is a 5.5% holding in AJOT. Media Contacts: KL Communications, AVI@kl-communications.com +44 (0)20 3882 6644 Ashton Consulting, avijapanpr@ashton.jp This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS Reach: https://www.londonstockexchange.com/news-article/AJOT/avi-urges-the-dismissal-of-two-directors-at-wacom/17592170

อ่านเพิ่มเติม
ACN Newswire 

Galaxy Payroll Group Limited Reports Improved Interim Results and Positive Operating Cash Flow

HONG KONG, May 14, 2026 - (ACN Newswire via SeaPRwire.com) - Galaxy Payroll Group Limited (NASDAQ: GLXG) (“GLXG” or the “Company”), a provider of payroll outsourcing and employment services, today announced its unaudited financial results for the six months ended December 31, 2025.Financial Highlights· Revenue increased to HKD14.0 million (US$2.0 million), representing year-over-year growth of approximately 2%· Total number of customers increased from 196 to 210· Net loss improved significantly from HKD26.5 million (US$3.4 million) to HKD1.1 million (US$0.1 million)· Operating expenses declined substantially following normalization of prior-period non-recurring expenses· Net cash provided by operating activities was HKD1.25 million (US$0.2 million)· Cash balance increased to HKD33.2 million (US$4 million) as of December 31, 2025The Company’s employment services business continued to expand across multiple Asian markets, supported by growing demand for cross-border employment and outsourcing solutions.The substantial reduction in net loss compared to the prior period primarily reflected the absence of certain one-time research and development expenditures and listing-related costs incurred during the prior fiscal year.For the full interim unaudited financial statements for the six months ended December 31, 2025, please refer to the report of foreign issuers furnished by the Company with the United States Securities and Exchange Commission on the even day of this release.Business UpdateThe Company has also observed encouraging business activity entering 2026, including increases in client headcount across selected accounts and continued onboarding of projects in multiple markets. These observations are preliminary in nature and may not necessarily be indicative of future financial results.Capital PositionAs of December 31, 2025, the Company maintained cash and cash equivalents of approximately HKD33.2 million (US$4 million) and positive working capital. Management believes the Company’s current liquidity position supports its present operating plan and ongoing business development activities.Based on current expectations, the Company does not currently expect to require near-term external equity financing and has no present intention to establish an at-the-market (“ATM”) offering program over the next 12 months. This assessment remains subject to market conditions, business performance, and strategic considerations.Management CommentaryWai Hong Lao, Chief Executive Officer of GLXG, commented:“Our interim results reflect continued progress in stabilizing and strengthening our operating profile following our public listing. While revenue growth remained modest during the period, we achieved meaningful improvement in our cost structure and operating performance.We are encouraged by the continued expansion of our customer base, positive operating cash flow, and ongoing business activity entering 2026. We remain focused on disciplined execution, prudent capital management, and building long-term shareholder value.”About Galaxy Payroll Group LimitedGalaxy Payroll Group Limited is a provider of payroll outsourcing and employment services operating across multiple Asian markets.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, but are not limited to, market conditions, customer demand, competitive conditions, regulatory developments, financing conditions, and the Company’s ability to execute its business strategy. Forward-looking statements include statements regarding future business activity, growth expectations, liquidity, and financing intentions. The Company undertakes no obligation to update forward-looking statements except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Euro Manganese Announces Positive Preliminary Economic Assessment

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 14, 2026) - Euro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E060) and its subsidiary Mangan Chvaletice, s.r.o. ("Mangan" and together the "Company", "Euro Manganese" or "EMN") is pleased to announce the results of a new Preliminary Economic Assessment ("PEA") for the development of its Chvaletice Manganese Project ("Chvaletice Manganese Project", "CMP", or "Project") in the Czech Republic.The PEA is a result of the Company's Optimization Program previously announced1, and builds on the extensive knowledge presented in the Company's Technical Report and Feasibility Study for the Chvaletice Manganese Project, Czech Republic, dated effective July 27, 2022[2], (the "2022 Feasibility Study"). The PEA responds to current market conditions and incorporates the Company's testing campaigns, demonstration plant learnings, and prospective customer testing and feedback to provide an updated preliminary and conceptual development path for the Chvaletice Manganese Project.With most permits secured, a finalized Environmental Impact Assessment ("ESIA"), and official designation as a Strategic Deposit under Czech law and a Strategic Project under the EU Critical Raw Materials Act, Euro Manganese is ready to respond to customers seeking a fully traceable battery-grade manganese supply chain, reducing dependence on Chinese sources and supporting strategic mineral independence objectives.The Chvaletice Manganese Project is well placed to take advantage of U.S. federal procurement and incentive frameworks that increasingly require that critical battery materials — including high-purity manganese used in electric vehicle and energy storage applications — be sourced from allied and US National Defense Act ("NDAA") compliant nations. The Czech Republic, as a NATO member and close U.S. ally, qualifies as an NDAA-compliant source country.HIGHLIGHTS(All economic values are in US dollars unless indicated otherwise)Strong Operating Margin of 48%, demonstrating resilience of the Project and the potential to generate significant returns across commodity price cycles.Robust Returns: Pre-tax IRR of 16.0% and Post-tax IRR of 13.8%, underpinned by a pre-tax NPV of $740M and post-tax NPV of $492M (8% discount rate), showing favorable preliminary economic indicators on historically conservative pricing assumptions.Higher Recoveries, 60% for High-Purity Manganese Sulphate Monohydrate (HPMSM) and 61% for High Purity Manganese Metal (HPEMM), reflecting additional metallurgical test work, operational learnings from the demonstration plant, and process engineering updates.Revised Flowsheet supports 50,000 tpa of HPEMM with full conversion to 150,000 tpa of HPMSM, aligning with battery industry demand while maintaining flexibility to deliver both HPEMM and HPMSM products as customer needs evolve.Newly incorporated magnesium carbonate ("MgCO3") resource as a by-product enables production of up to 20,000 tpa MgCO3, adding incremental value with minimal capital.CAPEX costs remain broadly consistent with the 2022 Feasibility Study, including with increased HPMSM output, despite an inflationary environment.OPEX reduced for per unit cost of HPMSM compared to the 2022 Feasibility Study, due to increased production of HPMSM and updated reagents and energy costs.Updated pricing assumptions demonstrates potential economic viability of the Project even under conservative current market conditions, underscoring its durability through price cycles.Phased development reduces upfront capital requirements, lowers funding risk, and allows further optimization before full-scale expansion.Phase II buildout planned shortly after Phase I commissioning to maximize project value and shareholder returns.Initial Capital, Phase One (50% capacity): $627.5M; Plant Capacity Expansion Capital, Phase Two (to 100% capacity): $197.8M.Annual nominal production: 150,000 tpa HPMSM.Project life: 26 years.Average life of project HPMSM price assumed at $2,888 per tonne.NEXT STEPSThe PEA has enabled the Company to optimize inputs based on current pricing, establishing the possibility for a two-stage construction strategy. This phased approach has the potential to allow for further optimization in phase two, lower upfront capital requirements, and enhance project economics by aligning investment with cash flow.The Company will now advance the Chvaletice Manganese Project further towards a full feasibility study, with a targeted completion in H1 2027.The Company will also continue to monitor high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies.The Company will continue to engage with potential customers to secure additional offtake term sheets, pursue offtake agreements, and continue product testing.In addition, during 2026, the Company is focused on the following key priorities to position the Project for its next development phase by:Advancing the financing strategy by securing funding for Project priorities and progressing strategic financing discussions with potential partners;Completing the acquisition of, or access to, the remaining land surface rights required for full Project development;Strengthening the Project's regulatory foundation through the continuous advancement of permitting, further reducing development risk and demonstrating Project readiness; andMaximizing non-dilutive capital by actively pursuing grants and incentives available from the EU and the Czech state.Martina Blahova, President & CEO of Euro Manganese, commented:"The publication of these PEA results marks another important milestone for the Chvaletice Manganese Project. Our recent optimization work has delivered measurable improvements in recovery, confirming both the strength of our technical strategy and the reliability of our process. To enhance capital efficiency and align investment with market demand, we have adopted a phased construction approach that maximizes value while reducing execution risk. The addition of by-product revenue stream further incrementally strengthens the economics of the project."This disciplined approach, coupled with conservative product pricing assumptions, supports a robust project profile with a strong operating margin of 48%, underscoring the Project's ability to perform through market cycles. Despite the challenging market and pricing conditions, the PEA results demonstrate the strength and resilience of the Project. It provides a clear pathway to unlocking the full long-term value of the Chvaletice Manganese Project as demand accelerates for localized, traceable, and sustainably produced battery grade high purity manganese. We are built to perform in volatile markets, engineered for operational efficiency, and positioned to play a strategic role in securing resource independence and reducing vulnerability amid an increasingly complex global landscape."Rick Anthon, Chairman of Euro Manganese, commented:"As a Board, we are encouraged by the progress reflected in this PEA and confident the Chvaletice Manganese Project can deliver on these terms for its shareholders, customers and stakeholders. The team has advanced the Project with a clear focus on technical rigour, capital efficiency, and responsible development. The phased construction strategy and strengthened economic profile demonstrate a thoughtful approach to building a long-life asset that can scale with market demand."With no operating manganese mines in Europe and as the only integrated high purity manganese producer in Europe and North America, the Chvaletice Manganese Project is uniquely positioned to become a cornerstone of Europe's emerging battery materials supply chain. The Project's strategic relevance, combined with its strong environmental credentials and growing commercial traction, reinforces our confidence in its long-term value. We believe the foundations are now firmly in place for Chvaletice Manganese Project to move toward the next stage of development and deliver meaningful returns for shareholders."PEA SUMMARY AND ECONOMIC ANALYSISThe PEA was completed by Tetra Tech Canada Inc. ("Tetra Tech"). A NI 43-101 technical report on the PEA will be filed under the Company's profile on SEDAR+ within 45 days of this news release and made available on the Company's website. A JORC report will be lodged with the Australian Securities Exchange ("ASX") ASX shortly thereafter.The following summarizes the material assumptions used in, and the results of, the PEA, assuming a targeted start of production in 2032.The Czech corporate income tax rate is 21%. In addition to the royalty of CZK 2,308 per tonne of unit Mn produced, the Czech Republic has various payroll and other taxes to generate revenue.The Company has modeled the economics of this project conservatively from a tax perspective, with a full tax burden, based on Czech legislated tax rates.Investment incentives exist in the Czech Republic and the European Union for certain, qualified investments, including investment tax credits, grants, and accelerated depreciation.The Company is actively pursuing these non-dilutive funding opportunities, including investment tax credits, grants, and accelerated depreciation available under both Czech and EU frameworks.Sensitivity AnalysisA sensitivity analysis for the Chvaletice Manganese Project was carried out to determine the effects of key variables in relation to the post-tax NPV of $492 million at a real discount rate of 8%. The results of the sensitivity analysis are presented in Table 3 below.Initial and Sustaining Capital EstimatesCapital expenditure estimates have been prepared for both initial and sustaining capital. A projected summary timeline of scheduled capital costs is shown in Table 4.The expected initial capital expenditures (Table 4) for the Project, inclusive of capitalized operating startup costs, as estimated by Tetra Tech, as of Q1, 2026, are $627.5 million, including all development-related costs that will be incurred prior to the envisaged commencement of commercial operations. Capital costs incurred after startup are assigned to sustaining capital and are projected to be paid out of operating cash-flows (also see Table 5). Contingencies on initial capital expenditure have been added at appropriate percentages to each component of the Project, excluding capitalized operating costs, resulting in an overall contingency of $66.7 million or 15.5% of direct costs.The Project site is served by excellent existing infrastructure, including rail, highway, a gas pipeline, and water and is adjacent to an operating power plant. The proposed plant site is zoned for industrial use and is the site of the former process plant that produced the Chvaletice tailings.New and refurbished infrastructure that will be built to service the Project include a tailings excavation and handling facility: a south and north site connection utility bridge for transporting tailings slurry, return water pipes and the tube conveyor that returns a mixture of non-magnetic tailings and washed leach residue to the residue dry stacking area; a magnetic separation beneficiation plant; enclosed and winterized process plant buildings and various reagent storage facilities and product warehouse; an upgraded rail spur system with related loading/unloading facilities; an internal road network; an incoming electrical 400kV high voltage grid connection including rectifiers, transformers, GIS switchgear, and local distribution step-down transformers; a process equipment maintenance workshop; a mobile fleet maintenance workshop; spare part and maintenance supply warehouses; a comprehensive water management system, onsite laboratories; and general administrative offices.Operating Cost EstimateOnsite operating costs are expected to average $181.99 per tonne plant feed ($4.14 per kg Mn equivalent) with offsite operating costs estimated to average $31.73 per tonne plant feed ($0.72 per kg Mn equivalent), as shown in Table 5.Resource EstimateTetra Tech was engaged to oversee the planning and execution of sampling and assaying, to prepare the updated Resource Estimate for EMN's Chvaletice Manganese Project, to prepare the Technical Report in accordance with National Instrument 43-101 - Standards and Disclosures for Mineral Projects, and to prepare the independent JORC Code technical report in accordance with the Joint Ore Reserves Committee Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves 2012 Edition ("JORC Code"). The 43-101 Technical Report, entitled "Technical Report and Mineral Resource Estimate for the Chvaletice Manganese Project, Chvaletice, Czech Republic", with an effective date of December 8, 2018 ("the Mineral Resource Estimate"), was filed on SEDAR on January 28, 2019. The corresponding JORC Code technical report with an effective date of December 8, 2018, was lodged on the ASX on February 6, 2019.No additional drilling or data collection pertaining to the technical disclosure of mineral inventory has been undertaken since the completion of the Mineral Resource Estimate, and the effective date for Mineral Resource Estimate is revised to April 27, 2026.The Project's combined Measured and Indicated Resources now amount to 26,960,000 tonnes, grading 7.33% total manganese (tMn) and 5.86% soluble manganese (sMn), as detailed in Table 6 below.PROCESSING FACILITIES DESCRIPTIONTailings Extraction, Residue Storage Facility and ReclamationIn the tailings extraction plan, the three tailings cells will be excavated in a counterclockwise sequence, starting with Cell #3, followed by Cells #1 and #2. Tailings will be extracted using shovel excavators and hauled by truck to an intermediate re-pulping and a covered storage station located between Cells #1 and #2. The storage station will create a 5-day material stockpile. Re-pulped tailings will be fed to the magnetic separation plant via a slurry pipeline on a continuous basis.A filtered blend of non-magnetic tailings and washed leach residue materials from the process plant will be conveyed using a tube conveyor to the storage station and placed and compacted in the Residue Storage Facility (RSF). The excavated area exposed after extraction of the existing tailings will be lined with a geomembrane liner. The RSF will be constructed in stages to suit residue storage requirements and progressively covered to limit the footprint of residue exposed to the air at any given time.RSF design features include a geomembrane lined bottom, perimeter surface water diversion and a contact water collection system that is integrated with the overall site water management system. Dust management includes the implementation of modern dust suppression methods on open faces, interim stack surfaces and haul roads, as required.Progressive reclamation will be undertaken as an integrated part of the residue stacking procedure. The filtered residue cover will consist of a low permeability soil and/or geomembrane cover to inhibit erosion and infiltration, and a growth layer to support vegetation growth.The site is expected to be fully reclaimed and brought back into a productive community to be established in consultation with local communities, regulators and national government agencies. The RSF will be monitored during the post-closure period for geotechnical and environmental performance.High Purity Manganese Products Production FacilityThe processing facilities, including ancillary facilities, for HPMSM production from the CMP tailings were designed by Beijing General Research Institute for Mining ("BGRIMM") together with EMN and Tetra Tech, based on the comprehensive metallurgical test results conducted during the previous PEA and validated through bench scale tests during the feasibility study. Additional metallurgical tests to recover manganese from anode slimes from electrowinning circuit were also conducted to support this PEA.The study was based on the design work completed for the 2022 Feasibility Study which included process circuit and process equipment optimization. Key equipment items were sized and selected based on the FS design by upgrading HPMSM circuit from the nominal capacity of 100,000 t/a to 150,000 t/a. In addition, two additional circuits, one for manganese recovery from anode slimes produced from the electrowinning circuit using reductive leaching and one for sodium and potassium removal from the HPMSM crystallization circuit by incorporating a high-temperature crystallization bypass system. One additional circuit to convert the magnesium carbonate from waste to a saleable by-product is incorporated into the magnesium removal circuit.The CMP process plant has been designed for a nominal nameplate production capacity of 150,000 tonnes per annum of HPMSM by processing approximately 1.1 million tonnes of the historical tailings per year.HPMSM is produced by converting HPEMM flakes produced by electrowinning process without the use of selenium and chromium. This product is expected to best meet the high purity manganese market demand anticipated in current and future battery formulations.The CMP HPMSM product is designed to contain no less than 99.9% high purity manganese sulfate monohydrate and a minimum of 32.34% manganese and will be sold in powder form, produced without the use of fluorine.The dried HPMSM powder product will be packed prior to being shipped in trucks or containers to customers .The process includes following unit circuits:High-intensity wet magnetic separation circuit, upgrading the excavated tailings manganese grade to approximately 15% tMn for acid leaching.Magnetic concentrate sulfuric acid leaching, neutralization to remove impurities and solid-liquid separation.Pregnant leach solution deep purification to further remove heavy metals.Manganese electrowinning to produce high purity HPEMM (high-purity electrolytic manganese metal) flakes using a selenium free process.A magnesium removal process circuit to ensure efficient electrowinning operations and high-quality product and magnesium carbonate produced as a by-product.HPEMM dissolution, solution purification and HPMSM crystallization and drying to produce battery-grade HPMSM for sale.Other supporting circuits, such as ammonium recovery system, water management systems, steam generation. The proposed process flow sheet is illustrated in Figure 1 below.Figure 1: Updated Simplified Process FlowsheetTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/11453/297390_4c2a5f3814e549ad_001full.jpgENVIRONMENTAL IMPACTS, PERMITTING AND COMMUNITY ENGAGEMENTEnvironmental impacts are monitored over the long term as part of the project. The ESIA process was conducted in two phases, supplemented by several expert studies and on-site monitoring. The result of the ESIA process, which involved participation from relevant authorities and the public, is the positive Environmental and Social Binding Statement, which was issued by the Ministry of Environment in March 2024. The ESIA permit is a crucial permit demonstrating that the assessed impacts on individual environmental components and the social sphere are acceptable and that the project is feasible.The assessment results show that the implementation of the project will not worsen existing environmental conditions and will not have negative social impacts. Furthermore, the realization of the project will reduce the identified contamination of groundwater and surface water in the tailings and its vicinity, where the source of the pollution is demonstrably deposited material. As the deposit is of anthropogenic origin and the mined material is a waste-product, this constitutes the reuse or recycling of waste, aligning with the principles of the circular economy. The aim of remediation and reclamation is to create a near-natural area with high biodiversity and stability, which will be used for recreational and sports activities.The ESIA process is followed by a subsequent permitting process when a significant portion of the permits had already been obtained, such as the Permit for the location of the processing plant, the Permit for the location of the rail spur, Product registration under the EU's REACH Regulation, and other permits related to auxiliary activities (utility relocations, grid connection, and others). Another key permit is the Determination of the Mining Lease Permit, which was granted to MANGAN Chvaletice, s.r.o on January 23, 2025; this is another crucial permit which authorizes the company to conduct mining activities. In the following steps, the company will undergo the permitting process stipulated by the Building Act, followed by the final operating permit.In 2026, the Company will continue to advance the permitting process under the Building Act, targeting completion of the final operating permit pathway in line with the feasibility study timeline. Each permitting milestone achieved further reduces Project risk and reinforces the Company's readiness to move into the next phase of development.Key Highlights of the Social Commitment:Significant Economic Catalyst: The Project will act as a primary economic driver in the Pardubice Region, creating 800-1,000 jobs during construction and providing stable, long-term employment for approximately 400 direct staff during operations, with a strong 85% local hiring commitment.Commitment to Transparency: The Project has established a robust engagement framework, including a dedicated public information center in Chvaletice and dedicated digital platforms (project-specific website and online grievance tools).Validated Social Acceptance: On March 27, 2024, the Czech Ministry of the Environment issued a favorable binding ESIA opinion, confirming that the Project meets the highest environmental and social standards. The Project currently faces no material barriers to acceptance, reflecting a strong Social License to Operate.BENEFITS OF PEA AND NEXT STEPSThe PEA enabled the Company to optimize inputs based on current pricing, establishing the possibility for a two-stage construction strategy. This phased approach has the potential to allow for further optimization in phase two, lower upfront capital requirements, and enhance project economics by aligning investment with cash flow. The Company plans to explore this and other avenues to advance the Chvaletice Manganese Project further towards feasibility study, with targeted completion in H1 2027.The Company will also continue to monitor high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies. The Company will continue to engage with potential customers to secure additional offtake term sheets, pursue offtake agreements, and continue product testing.In addition, during 2026, the Company is focused on the following key priorities to position the Project for its next development phase by:Advancing the financing strategy by securing funding for Project priorities and progressing strategic financing discussions with potential partners;Completing the acquisition of, or access to, the remaining land surface rights required for full Project development;Strengthening the Project's regulatory foundation through the continuous advancement of permitting, further reducing development risk and demonstrating Project readiness; andMaximizing non-dilutive capital by actively pursuing grants and incentives available from the EU and the Czech state.Competent and Qualified Person StatementAll production targets for the Chvaletice Manganese Project referred to in this news release are underpinned by estimated Measured and Indicated Mineral Resources prepared by Competent Persons and Qualified Persons in accordance with the requirements of the JORC Code and NI 43 - 101, respectively. Additionally, the scientific and technical information included in this news release, is based upon information prepared, verified, and approved by Mr. James Barr, P. Geo, Senior Geologist, Mr. Jianhui (John) Huang, Ph.D., P. Eng., Senior Metallurgical Engineer, Mr. Hassan Ghaffari, P.Eng, M.A.Sc., Senior Process Engineer, Mr. Chris Johns, P.Eng, Senior Geotechnical Engineer, and Mrs. Maurie Marks, P.Eng, Senior Mining Engineer, all with Tetra Tech. Mr. Barr, Mrs. Marks, Mr. Ghaffari, Mr. Johns, Mr. Hasanloo and Mr. Huang are consultants to, and independent of, EMN within the meaning of NI 43-101, and have sufficient experience in the field of activity being reported to qualify as Competent Persons as defined in the JORC Code, and are Qualified Persons, as defined in NI 43-101. Mr. Barr is responsible for the Mineral Resource Estimate, Mr. Huang is responsible for the metallurgical test work results, process engineering, operating cost and capital cost estimates, environmental studies, permitting, and social or community impact. Mr. Ghaffari is responsible for infrastructure, Mrs. Marks is responsible for mining and financial analysis, Mr. Johns is responsible for design of the residue storage facility. Mr. Barr visited the property during the 2017 drilling program and again during the 2018 drilling campaign, on July 30-31st, 2018, during which time he observed the drilling, sample collection and preparation, sample logging and sample storage facilities. Mr. Huang visited the Project site on February 5, 2018 and May 3, 2022, as well as visited the Changsha Research Institute of Mining and Metallurgy Co. ("CRIMM") laboratory and pilot plant facility five times between January 20, 2017 and September 20, 2018 to witness sample preparation and test/assay facilities and to discuss the test program and results with CRIMM's technical team. Mr. Huang also visited the SGS Minerals Services (SGS) laboratory on June 29, 2017, and oversaw the bench scale validation test work completed by BGRIMM. Mrs. Marks, Mr. Johns and Mr. Ghaffari also visited the project site on May 3, 2022. Barr, Huang, Ghaffari, Johns and Marks have no economic or financial interest in the Company and consent to the inclusion in this news release of the matters based on their information in the form and context in which it appears.In addition, technical information concerning the Chvaletice Manganese Project is reviewed by Dr. David Dreisinger, P. Eng, a Qualified Person under NI 43-101. Dr. Dreisinger has reviewed and approved the information in this news release for which he is responsible and has consented to the inclusion of the matters in this news release based on the information in the form and context in which it appears.Cautionary StatementThe PEA is a high-level review of potential, is preliminary in nature, and there is no certainty that the economics in the PEA will be realized. The PEA results are not equivalent to, and should not be construed as, a Pre-Feasibility Study or Feasibility Study. Accordingly, investors are reminded that the PEA is considered preliminary in nature and includes estimated costs that are subject to an approximate margin error of plus or minus 35%. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability, and there is no guarantee the Project's resources will eventually be classified as reserves.The projected process plant design, potential production profile and project plan are conceptual in nature and additional technical studies will need to be completed in order to fully assess their viability. There is no certainty that a potential production decision will be made, or that a commercial operation will be achieved.A sensitivity analysis for the Project was carried out to determine the effects of key variables in relation to the post-tax NPV of US$492 million using a real discount rate of 8%. The results of the sensitivity analysis are presented in Table 3 of this announcement. Additional sensitivities from changes in capital and operating costs, recoveries, and metal prices are also included in Table 3.The PEA is also based on the material assumptions outlined in this announcement. These include assumptions about the availability of funding. While EMN considers all of the material assumptions to be based on reasonable grounds, including those related to funding, there is no certainty that they will prove to be correct or that the range of outcomes indicated by the PEA can be achieved.To achieve the range of outcomes indicated in the PEA, funding in the order of approximately US$670.9 million is assumed to be required for initial capital expenditures and working capital. It is anticipated that funding will be sourced through a combination of equity and debt, and possibly other means; however, given that the PEA is considered preliminary in nature, the Company expects to finalize its financing strategy for the Project in conjunction with, or after, the completion of the feasibility study.Investors should note that there is no certainty that EMN will be able to raise that amount of funding when needed. It is also likely that such funding may only be available on terms that may be dilutive to or otherwise affect the fundamental value of EMN's existing shares. It is also possible that the Company could pursue other 'value realisation' strategies such as a sale, partial sale or joint venture of the Project. If such strategies are pursued, it could materially reduce EMN's proportionate ownership of the Project. Given the uncertainties involved, investors should not make any investment decisions based solely on the results of the PEA.Euro Manganese is dual listed on the TSX-V and the ASX. Neither TSX Venture Exchange nor its Regulation Services Provider (as defined by TSXV policies) or the ASX accepts responsibility for the adequacy or accuracy of this release.Authorized for release by the President and CEO of Euro Manganese Inc.Martina BlahovaPresident and CEO+1 (604) 681-1010info@mn25.caJane Morgan ManagementJane MorganInvestor and Media Relations - Australia+61 (0) 405 555 618jm@janemorganmanagement.com.auLodeRock AdvisorsNeil WeberInvestor and Media Relations - North America+1 (647) 222-0574neil.weber@loderockadvisors.com  About Euro ManganeseEuro Manganese Inc. (TSXV: EMN) (ASX: EMN) (FSE: E060) is a battery materials company developing the Chvaletice Manganese Project in the Czech Republic, Europe's only near-term source of high-purity manganese, a critical ingredient in next-generation electric vehicles, energy storage batteries and defence applications.The Chvaletice Manganese Project aims to reprocess historic mine tailings to produce high-purity electrolytic manganese metal (HPEMM), and high-purity manganese sulphate monohydrate (HPMSM), establishing a fully traceable, low-carbon supply chain within the European Union.Euro Manganese is positioned to become Europe's first domestic producer of high-purity manganese, meeting the rising demand for sustainable, strategic battery materials while advancing Europe's clean-energy and supply-chain independence goals.Forward-Looking StatementsCertain statements in this news release constitute "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the Company, its Chvaletice Project, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.Readers are cautioned not to place undue reliance on forward-looking information or statements. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements and, even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company.Forward looking information or statements include all of the results of the PEA, including estimates of internal rates of return (including any pre-tax and after-tax internal rates of return, payback periods, net present values, future production, estimates of cash cost, assumed prices for HPEMM and HPMSM and by-products, proposed extraction plans and methods, operating life estimates, cash flow forecasts, metal recoveries and estimates of capital and operating costs. Forward looking statements also include the possibility for a two-stage construction strategy, and the potential to allow for further optimization of the Project in phase two, with lower upfront capital requirements, and to enhance project economics by aligning investment with cash flow. The Company has based its assumptions and analysis on certain factors that are inherently uncertain, including (i) the adequacy of infrastructure; (ii) the ability to develop adequate processing capacity; (iii) the price of HPEMM and HPMSM and by-products; (iv) the availability of equipment and facilities necessary to complete development; (v) the size of future processing plants and future tailings extraction rates; (vi) the cost of consumables and extraction and processing equipment; (vii) unforeseen technological and engineering problems; (viii) currency fluctuations; (ix) changes in laws or regulations; (x) the availability and productivity of skilled labour; and (xi) the regulation of the mining industry by various governmental agencies.Forward-looking statements also include statements regarding the Company's strategy for its Chvaletice Project, ability to access high purity manganese markets and strategic sectors to which it contributes, including energy transition, grid-scale energy storage, e-mobility and aerospace and defence technologies and sell its products, the ability to complete a feasibility study in 2027, and the Company's ability to navigate current market conditions. In addition, forward-looking statements include statements regarding the Company's next steps including: advancing financing efforts; seeking strategic partners, finalizing product testing, and negotiating offtake agreements with customers; Securing remaining land access; progressing key permits; and pursuing government funding.All forward-looking statements are made based on the Company's current beliefs including various assumptions made by the Company, including that the Chvaletice Project will be developed and operate as planned, the results of the PEA are reliable, that the Company will have sufficient financing to continue operations, and that the Company will be able to meet the conditions of its secured financing. Factors that could cause actual results or events to differ materially from current expectations include, among other things: results from the PEA are not accurate; insufficient working capital; inability to meet the conditions of its secured financing, risks due to granting security, lack of availability of financing for developing and advancing the Chvaletice Project; no available government funding or incentives; the potential for unknown or unexpected events to cause contractual conditions to not be satisfied; developments in electric vehicle battery markets and chemistries; risks related to fluctuations in currency exchange rates; and changes in laws or regulations by various governmental agencies. For a further discussion of risks relevant to the Company, see "Risk Factors" in the Company's annual information form for the year ended September 30, 2025, available on the Company's SEDAR+ profile at www.sedarplus.ca.Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release and are expressly qualified in their entirety by this cautionary statement. Subject to applicable securities laws, the Company does not assume any obligation to update or revise the forward-looking statements contained herein to reflect events or circumstances occurring after the date of this news release. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297390 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Assembly Rolls out Stagwell Search+ Across APAC as AI Reshapes Brand Discovery

HONG KONG, May 14, 2026 - (ACN Newswire via SeaPRwire.com) - As search becomes increasingly AI-led and zero-click, brands need new strategies to shape how they appear in answers, not just in links. APAC has emerged as a global leader in AI Search adoption, with 78% of users reporting weekly usage. Increasingly, AI Search Experiences shape brand discovery and consideration before users ever visit a website.In response, global omnichannel media agency Assembly today announced the rollout of Stagwell Search+ in APAC - a new system designed to help brands understand and influence how they are represented across AI-driven search environments.The launch marks a fundamental shift away from treating search as a standalone channel. Instead, Stagwell Search+ operates across a full ecosystem of paid, owned, earned, and shared media, where AI-generated answers determine visibility and performance. This shift is especially complex in APAC, where a fragmented landscape of large language models, spanning multiple languages and cultural contexts, creates inconsistent brand visibility. A brand may appear authoritative in one model while remaining invisible or misrepresented in another, introducing a new and largely unmeasured risk for marketers.Built by Assembly in partnership with emberos, Stagwell Search+ is powered by the industry's first agentic operating system for AI search. The platform continuously monitors how brands appear across models and languages and orchestrates & measures the lift from actions across content, media, and digital channels to improve visibility. Rather than automating changes directly into platforms, the system is designed to guide human decision-making with AI agents - helping teams take precise, strategic action while protecting the quality and integrity of brand experiences.Stagwell Search+ is currently integrated with leading global models from OpenAI, Gemini, Perplexity, Grok, and Anthropic with additional integrations across regional platforms such as DeepSeek planned for later this year."AI is already making brand decisions without marketers in the room - and in APAC, that challenge is amplified by language and cultural complexity," said Yi En Chye, VP of Experience and Activation, APAC. "Success is no longer defined by rankings or clicks, but by a brand's ability to secure share of prompt. Stagwell Search+ gives brands the visibility and control they need to compete in this new environment."ABOUT ASSEMBLYAssembly is a global omnichannel agency built for brands that want a more modern approach to building brands that perform. Backed by the Stagwell network, we are a literal assembly of data, talent, and technology built to unlock smarter, faster, and better-performing outcomes from the bottom up -not the top down. Curious, collaborative, and driven by change, we are an agency of builders who believe the better the experience, the better the performance. We don't see brand and performance as an either/or. For us, it's always both. The + symbol in our logo, known as the ORAD, represents this mindset. It's a mark of how we think, how we build, and how we deliver results across the full funnel. Assembly's foundation is built on three core elements: our purpose-built STAGE Experience Engine, the strategic product it powers-Brand Performance Planning (BPP) - and an organizational design built for speed, depth, and the demands of modern marketing. Together, they enable us to build better brand experiences that reimagine how brands connect, engage, and grow across data, tech, media, creative and commerce. With over 3,000 experts in 44 offices worldwide, Assembly delivers full-funnel solutions that help the world's most ambitious brands perform. Learn more at assemblyglobal.com.ABOUT STAGWELLStagwell is the global challenger network transforming marketing through AI. We deliver scaled creative performance for the world's most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our specialists in 45+ countries are unified under a single purpose: to drive effectiveness and improve business results for our clients. Join us at www.stagwellglobal.com.MEDIA CONTACTKelvin LeeMarketing Director, APACKelvin.lee@assemblyglobal.comSOURCE: Assembly Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Sherlocq Launches the First AI-Native Regulatory Intelligence Platform for Global Financial Services

NEW YORK, USA AND ABU DHABI, UAE, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Sherlocq, the first AI-native regulatory intelligence platform for global financial services, today announced its public launch. Designed for compliance officers, lawyers, risk professionals, and regulators who operate at the intersection of law, governance, and institutional accountability, Sherlocq delivers regulatory intelligence that is precise, traceable, and usable at institutional scale.The launch marks the emergence of a new category in enterprise AI: regulatory intelligence, a vertical distinct from generic AI assistants, conventional regtech monitoring tools, and document management platforms. Sherlocq has been built from the ground up to meet the security, privacy, and domain standards that regulated institutions require, and which no general-purpose AI platform has been designed to deliver.THE PROBLEMFinancial institutions, law firms, regulators, and consultants collectively spend over $300 billion every year on regulatory compliance. More than ten million professionals carry the weight of that complexity daily, tracking regulatory changes across dozens of jurisdictions, reviewing thousands of documents, and making high-stakes decisions that can determine the fate of institutions and individuals alike.Until now, the tools available have been fundamentally inadequate: monitoring without interpretation, alerts without answers, search without synthesis. Regulatory research has remained a largely manual process for decades. Vertical AI has already demonstrated category-defining value in adjacent domains. Regulatory intelligence represents a larger, more global, and more complex opportunity.Sherlocq changes that.THE PLATFORMAt launch, Sherlocq covers the regulatory output of governments, supervisory authorities, and enforcement bodies across 30+ jurisdictions, including the US, UK, UAE, Singapore, and Hong Kong. It ingests, structures, and indexes this information continuously, so when a compliance officer, lawyer, or risk professional asks a question, Sherlocq returns a precise, sourced, and traceable answer in seconds. Research that previously required hours of manual work across multiple sources is completed in under a minute.The platform launches with three live capabilities:Regulatory Research and Analysis - Multi-jurisdiction research, cross-border regulatory comparison, compliance framework analysis, and obligation mapping across the full spectrum of financial services regulation, covering all major regulated financial centres.Document Intelligence - Structured review, gap assessment, benchmarking, and policy analysis against applicable regulatory standards, available on the native Sherlocq platform.Sanctions Intelligence - Real-time, multi-regime sanctions research across OFAC, OFSI, EU, UAE, and 320+ data sources in a single query, with full source traceability. The first AI-native platform to deliver this level of depth and auditability across multiple sanctions regimes simultaneously.Sherlocq is available on web, iOS, and Android, for individual professionals and enterprise organisations. AI connectors are live for Claude and ChatGPT, enabling regulatory research to be accessed directly within the tools professionals already use. Microsoft Copilot and Google Gemini integrations follow shortly.Sherlocq is certified to ISO 27001 and ISO 27701 standards, meeting the security and data privacy requirements of regulated financial institutions globally.FOUNDER'S STATEMENT"I have spent my career sitting across the table from regulators, leading investigations at the highest levels, and advising institutions in the most consequential moments of their existence. In every one of those engagements, the same problem recurred: brilliant professionals, at world-class institutions, spending most of their time on research and cross-referencing that should have been automated years ago. Not because the technology did not exist. Because no one had built it with the rigour, the domain depth, and the institutional trust that this work demands. That is what we built. Sherlocq is not a general AI tool adapted for compliance. It is the intelligence infrastructure that this industry has always needed and never had," said Bhavin Shah, Founder and Chief Executive Officer, Sherlocq.ABOUT THE FOUNDERBhavin Shah is a globally recognised regulatory and compliance leader with over twenty years of experience advising sovereigns, regulators, boards, and financial institutions across their most complex and politically sensitive challenges. His career spans multi-jurisdiction investigations, AML and financial crime reform, regulatory negotiations, crisis management, and governance advisory across the US, UK, Middle East, and Asia Pacific. He has advised some of the world's most consequential regulatory reform processes and financial institutions at moments of institutional stress, enforcement risk, and strategic transformation.Shah is a World Economic Forum Young Global Leader (2020), a board member of the D2A2 digital assets and AI policy forum, and holds executive education credentials from Harvard Business School and Harvard Kennedy School. He serves as an independent non-executive director on the boards of regulated financial institutions, giving him direct and ongoing insight into the governance, compliance, and regulatory pressures that Sherlocq is designed to address.INDUSTRY VOICES"Regulatory complexity has been accelerating for years and this is only compounding with the recent trends toward fragmentation around the globe. The tools available to compliance professionals have not kept pace. Sherlocq addresses that gap in a way that is substantive, not superficial. What distinguishes this platform is that it has been built with a genuine understanding of how regulated institutions work and what they actually need to be more effective and more efficient. The depth, the traceability, and the institutional-grade approach reflect the kind of rigour that regulators and boards rightly expect. I am proud to support Bhavin and the Sherlocq team as they bring this important product to market," said Bryan Stirewalt, Former Chief Executive, Dubai Financial Services Authority; Former National Bank Examiner, Office of the Comptroller of the Currency; Board Advisor, Sherlocq."Running a banking group across more than 35 markets meant living with regulatory complexity as a daily operational reality. Our teams were talented and diligent but the tools available forced them into a process that was slow, fragmented and heavily manual. Sherlocq solves that problem. It gives compliance and legal professionals the structured multi-jurisdictional intelligence that I would have wanted for my team. This is the platform the industry has always needed,” said Arnold Ekpe, Former Group Chief Executive Officer, Ecobank Group; Board Advisor, Sherlocq.ABOUT SHERLOCQSherlocq Inc. is a US-incorporated AI technology company (Delaware) with principal offices in New York and Abu Dhabi, UAE, and the creator of the first AI-native regulatory intelligence platform purpose-built for global financial services. The company has completed a pre-seed financing round backed by investors across the US, UAE, and Europe. Designed for compliance officers, lawyers, risk professionals, regulators, and governance teams, the platform delivers multi-jurisdiction regulatory research, document intelligence, and sanctions intelligence, with workflow automation and deeper enterprise capabilities on the near-term roadmap. Sherlocq is certified to ISO 27001 and ISO 27701 standards and is available globally on web, iOS, and Android. Financial institutions, law firms, and professional services organisations seeking enterprise access are invited to contact hello@sherlocq.com. sherlocq.com | sherlocq.ai | hello@sherlocq.com MEDIA CONTACTFor media enquiries, interview requests with Bhavin Shah, or access to additional materials including product demonstrations, founder biography, and platform assets:Press contact: press@sherlocq.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Agnete Kirk Kristiansen Appointed Chair of the LEGO Foundation

BILLUND, DENMARK, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At the LEGO Foundation's annual meeting, the Board of Directors elected Agnete Kirk Kristiansen as Chair of the Board. As fourth generation member of the Kirk Kristiansen family, owners of the LEGO Group, she becomes only the fifth Chair of the Foundation since it was founded in 1986.Agnete Kirk Kristiansen has served as Deputy Chair of the LEGO Foundation since 2023 and replaces her brother Thomas Kirk Kristiansen who steps down to assume the position of Deputy Chair. In addition to her role at the LEGO Foundation, Agnete Kirk Kristiansen also serves as Deputy Chair of KIRKBI A/S, the family-owned holding and investment company that owns 75% of the LEGO Group.As ascending Chair, Agnete Kirk Kristiansen highlighted the role of the LEGO Foundation in building a brighter tomorrow for children around the world:I am truly honored to step into the role as Chair of the LEGO Foundation and to continue our important work for children. The foundation holds a very special place in our family and has done so ever since it was established more than 40 years ago. A deep sense of responsibility to make a positive difference for children runs through our family and I strongly believe that every child should have the opportunity to thrive and grow. I am proud to contribute to this mission and help carry it forward.The change in chair takes place the year after Agnete stepped into the role as chair of non-profit foundation Ole Kirk's Fond. With the transition, the fourth generation of the owner family is broadening its engagement and commitment to active ownership.Descending Chair Thomas Kirk Kristiansen said:It has been a privilege to chair the LEGO Foundation for the past 10 years, and I am very happy to now pass on the role to Agnete. She is deeply committed to the LEGO Foundation mission, and I know she will do her utmost to further the cause of securing a childhood for all. During her tenure as Deputy Chair, she has played an integral part in shaping the foundation's current strategy and as she steps into the role as Chair, we further widen the active ownership and engagement from the family across the LEGO ecosystem.Thomas Kirk Kristiansen has served as Chair of the LEGO Foundation since 2016 and in that period the foundation has committed grants of more than DKK 15 billion (EUR 2 billion) through partner organisations across the globe to improve children's outcomes.For 40 years, the LEGO Foundation has been focused on giving back and building a better world for children. We are very mindful of the trust families and communities place in us, and it is not a responsibility we take lightly. Even in the most challenging settings, the foundation can help put a smile on a child's face, lift up learners of all abilities and change life paths. We do so with the utmost sensitivity and responsibility, said Agnete Kirk Kristiansen.In addition to safeguarding the continued development and success of the LEGO Group as part-owner, the LEGO Foundation pursues its philanthropic mission to support initiatives within education, research, and child development through funding of and close collaboration with organisations such as Brac, IRC, UNICEF, Save the Children, Norwegian Refugee Council and others.Further changes to the LEGO Foundation BoardIn addition to Agnete and Thomas Kirk Kristiansen changing roles as Chair and Deputy Chair, the LEGO Foundation Board of Directors at its May meeting also elected as member of the Board Ingrid Stange, who brings a wealth of experience in philanthropy, education and non-profit leadership. Further, both Jørgen Vig Knudstorp, former CEO of the LEGO Group, and El Hadji Amadou Gueye Sy (As), former Secretary-General of the International Federation of Red Cross and Red Crescent Societies, left the Board after 16 and four years of service respectively to the LEGO Foundation.Thomas Kirk Kristiansen thanked the two departing Board members for their long-standing commitment to the foundation:We look very much forward to welcoming Ingrid, who brings highly complementary expertise to the board. At the same time, I thank As for bringing invaluable insights and experience to help shape our work.I would also like to extend my sincerest gratitude to Jørgen for his unwavering dedication to the foundation. During his extensive tenure, Jørgen has been instrumental in defining our vision and strategy while never losing sight of the children we are here to serve.Additionally, Malou Aamund, who has served on the Board since 2021, stepped into the role of Second Deputy Chair of the Foundation.Biography: Agnete Kirk KristiansenLEGO Foundation2026 - Chair of the Board of Directors2023 - 2026 Second Deputy Chair of the Board of DirectorsFrom 2008 Member of the Board of DirectorsKIRKBI A/S2024 - Deputy Chair of the BoardCentre for ADHD+, Aarhus, DenmarkFounderOle Kirk's Fond2025 - Chair of the BoardDegreePsychology, Aarhus University, 2010Additional roles, present and past:Executive Manager, KIRK83 Holding ApSMember of the Advisory Board, RucaRepresentative of the fourth generation of the LEGO owner familyExtensive experience in family-owned companies, long-term stewardship and board workLEGO Foundation Board of DirectorsAgnete Kirk Kristiansen - ChairThomas Kirk Kristiansen - First Deputy ChairMalou Aamund - Second Deputy ChairHilary Pennington - Member of the BoardIngrid Stange - Member of the BoardLEGO Foundation Board of Directors Chairs1986 - 1993: Gotfred Kirk Kristiansen (2nd-generation LEGO owner)1993 - 2000: Bent Skov2000 - 2016: Kjeld Kirk Kristiansen (3rd-generation LEGO owner)2016 - 2026: Thomas Kirk Kristiansen (4th-generation LEGO owner)2026 - Agnete Kirk Kristiansen (4th-generation LEGO owner)About LEGO Fonden:The LEGO Foundation is a Danish corporate foundation entrusted with 25 % ownership of the LEGO Group. The Foundation works with partners around the world to support children's needs and champion the dignity of childhood. Through both philanthropic donations and impact investments the Foundation exists to build the conditions and create the space for every child, everywhere, to thrive and grow. More information about the LEGO Foundation can be found at: https://www.legofoundation.com/Contact information:Mads Hvitved Grandmads.hvitved.grand@legofoundation.comSOURCE: LEGO Fonden Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunitiesTAMPA, FLA., May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.com[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

S&P Tear Sheet: GTJAI Continues to Play a Key Role in the Group’s International Strategy

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, in its latest Tear Sheet, S&P Global stated that it expects Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, and its intermediate holding company Guotai Haitong Financial Holdings Ltd.  (“GTHTFH”), to continue to play a key role in the international strategy of their ultimate parent Guotai Haitong Securities Co. Ltd. (“GTHT”).In its Tear Sheet, S&P Global pointed out that the business synergies between GTJAI and its parent company, particularly in investment banking and wealth management, reinforce its importance within the group. International development is one of GTHT’s core strategic priorities, and GTJAI will continue to play a key role in the Group’s efforts to strengthen its global presence. In 2025, GTJAI and GTHTFH recorded 284% and 85% profits growth, respectively, and accounted for about 3% and 8% of GTHT’s net profit during the year. This strong financial performance robustly demonstrates the Company’s contribution to the overall business of the Group.S&P Global expects that GTJAI will remain one of the Group’s core subsidiaries over the next two years and will continue to receive support from GTHT, with its issuer credit rating and “stable” outlook moving in tandem with those of the parent. S&P Global believes that GTJAI has access to timely parental support, including indirect benefits from the Shanghai government through GTHT if needed.This Tear Sheet fully reflects the Company’s current situation and expectations for future development. GTJAI will resolutely align with the Group’s international strategy, continuously enhance its own professional capabilities and the efficiency of business synergies with the Group, and contribute to Guotai Haitong Group’s goal of becoming a first-class investment bank with international competitiveness and market leadership.Note: This article is based on an independent opinion document (Tear Sheet: Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.) published by S&P Global Ratings on May 5, 2026. This document does not constitute a rating action.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com.     Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair concluded successfully

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in  disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in  areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.”  Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product  Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Nissin Foods Announces 2026 Q1 Financial Results

 Financial HighlightsFor the three months Ended 31 March 2026(HK$ million)20262025ChangeRevenue 1,115.61,071.9+ 4.1%Gross Profit402.1376.1+ 6.9%Gross Profit margin36.0%35.1%+ 0.9ppProfit attributable to owners of the Company122.4110.0+ 11.3%Net profit margin11.0%10.3%+ 0.7ppAdjusted EBITDA 209.0201.5+ 3.7%Earnings per share (HK cents)11.7310.54+ 11.3%HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its unaudited first quarter financial results for the three months ended 31 March 2026 (the “Reporting Period”).The Group reported revenue of HK$1,115.6 million for the Reporting Period, representing an increase of 4.1% from HK$1,071.9 million of the corresponding period of 2025. Gross profit increased by 6.9% year-on-year to HK$402.1 million, due to the continued implementation of cost efficiency initiatives. Gross profit margin increased by 0.9 percentage points to 36.0% from 35.1% of the corresponding period of 2025 mainly attributable to the increased sales volume of the core brands to absorb cost pressure. Profit attributable to owners of the Company notably increased by 11.3% year-on-year to HK$122.4 million, while Adjusted EBITDA grew by 3.7% year-on-year to HK$209.0 million.Revenue from Hong Kong and other regions operations increased moderately by 3.1% due to the stable performance of the noodles business, particularly the Group’s core brands of Cup Noodles and Demae Iccho. As for the Chinese Mainland operations, revenue increased by 4.6% due to the sales expansion in the inland areas and the appreciation of Renminbi to Hong Kong Dollars.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Building on the solid momentum established in 2025, the Group delivered another quarter of resilient growth, with steady performance across our key markets. Revenue and profitability improved year-on-year, supported by stable sales volumes. Our core noodles business continued to perform well across regions, while our premiumisation and diversification strategies gained further traction in the Chinese Mainland. With a balanced regional footprint and enhanced operational execution, the Group remains well positioned to deliver sustainable growth and long-term value for shareholders.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

SAP Unveils the Autonomous Enterprise

ORLANDO, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers,‘almost right’just isn’t good enough,” said Christian Klein, CEO of SAP SE,“By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม
ACN Newswire 

Dr. Shui On Leung Invited to the 2026 LifeArc Translational Science Summit in the UK

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab’s R&D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year’s summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung’s invitation to this high-profile event marks high recognition from leading international authorities of SinoMab’s innovative efforts in immunotherapy.In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&D for autoimmune disease therapeutics, and elaborated on SinoMab’s differentiated innovation framework anchored in “First-in-Class” and “Best-in-Class” drug development. He gave a detailed introduction to SM17, the Company’s flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn’s disease and ulcerative colitis was officially approved by China’s National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company’s innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab’s innovative edge and exploratory work in antibody R&D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China’s biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies.  This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeNomia ZhouQiuyan DengPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

อ่านเพิ่มเติม